Understanding the biology of low von Willebrand Factor and Type 1 von Willebrand Disease
Official title: Multi-Omics Data Integration for Understanding the Biology of VWD
Funded at Washington University · NIH-11016814 · Data updated 2026-11-12
This study is looking at what causes low levels of von Willebrand Factor and Type 1 von Willebrand Disease, which can lead to unusual bleeding, by examining genetic and health information from a variety of patients over time to find new ways to help manage these conditions better, especially as people age.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | May 15, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $337,602 |
| NIH project number | 1P01HL173579-01A1 |
| Project ID | NIH-11016814 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with low von Willebrand Factor or Type 1 von Willebrand Disease, particularly those experiencing age-related changes in bleeding risk.
✕Less likely to help
Patients with other bleeding disorders unrelated to von Willebrand Factor or those without a diagnosis of VWD may not benefit from this research.
What this research studies
This research investigates the complex factors contributing to low von Willebrand Factor (VWF) and Type 1 von Willebrand Disease (VWD), which are conditions that lead to abnormal bleeding. By utilizing advanced multi-omics technologies, the study aims to analyze genetic, molecular, and clinical data from a diverse group of patients over time. The goal is to identify disrupted biological pathways and molecular signatures that contribute to these bleeding disorders, particularly in relation to aging. This comprehensive approach may reveal new therapeutic targets for better management of these conditions.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and management strategies for patients with low VWF and Type 1 VWD.
How similar studies have gone: Previous research utilizing multi-omics approaches has shown promise in uncovering complex biological mechanisms in various diseases, suggesting potential success for this novel investigation.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Sadler, Brooke — Washington University
- Study coordinator: Sadler, Brooke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.